Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.54 |
| ▸ | HLCS | P50747 | 6/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337427 | 0.87 | HLCS (0.58) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL6159219 | 0.86 | HLCS (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL7545265 | 0.85 | TDP1 (0.55) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5341777 | 0.85 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5804916 | 0.84 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5817718 | 0.84 | HLCS (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL739034 | 0.84 | TDP1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29512013 | 0.84 | TDP1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL30800274 | 0.84 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31378057 | 0.84 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040462-B2 | In vivo production of cyclic peptides for inhibiting protein-protein interaction | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2001066565-A9 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES | RIGEL PHARMACEUTICALS INC (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20080261819-A1 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES FOR INHIBITING PROTEIN-PROTEIN INTERACTION | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1575553-A4 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES FOR INHIBITING PROTEIN-PROTEIN INTERACTION | RIGEL PHARMACEUTICALS INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7378248-B2 | In vivo production of cyclic peptides for inhibiting protein-protein interaction | RIGEL PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7252952-B2 | In vivo production of cyclic peptides for inhibiting protein—protein interaction | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070105140-A1 | In vivo production of cyclic peptides | NUFARM AMERICAS INC. | 2007-05-10 | — | — | US | disclosed |
| US-7208571-B2 | In vivo production of cyclic peptides | RIGEL PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7141366-B1 | Surface display of selenocysteine-containing peptides | NEW ENGLAND BIOLABS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-7105341-B2 | In vivo production of cyclic peptides | RIGEL PHARMACEUTICALS. INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050260626-A1 | In vivo production of cyclic peptides for inhibiting protein-protein interaction | RIGEL PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050233456-A1 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES | RIGEL PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1575553-A2 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES FOR INHIBITING PROTEIN-PROTEIN INTERACTION | Rigel Pharmaceuticals, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050158820-A1 | In vivo production of cyclic peptides | RIGEL PHARMACEUTICALS, INC. | 2005-07-21 | — | — | US | disclosed |
| US-20050048548-A1 | Surface display of selenocysteine-containing peptides | NEW ENGLAND BIOLABS, INC. | 2005-03-03 | — | — | US | disclosed |
| WO-2004019890-A2 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES FOR INHIBITING PROTEIN-PROTEIN INTERACTION | RIGEL PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-20040014100-A1 | In vivo production of cyclic peptides for inhibiting protein-protein interaction | RIGEL PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| EP-1263777-A2 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES | Rigel Pharmaceuticals, Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066565-A2 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES | RIGEL PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2000070100-A1 | SURFACE DISPLAY OF SELENOCYSTEINE-CONTAINING PEPTIDES | NEW ENGLAND BIOLABS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050158820-A1 | In vivo production of cyclic peptides | VIP, NGLY1, FURIN | TDP1 1683/4885MEN1 1741/4885ABL1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.